Skip to main content
SpringerLink
Log in

Slow-release lanreotide in Graves’ ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

SS analogs are an attractive alternative in treating Graves’ ophthalmopathy (GO). Most of the previous studies were uncontrolled and enrolled few patients. The present study was conducted as a larger scale, prospective, randomized controlled study to determine the effectiveness of a slow-release formulation of lanreotide in GO. Sixty patients with active GO received an im injection every two weeks of either lanreotide 30 mg or placebo for 12 weeks. They were then followed and further treated in the traditional way if necessary. The Clinical Activity Score (CAS) was the primary efficacy criterion. Proptosis, diplopia, corneal erosion or ulcer, visual acuity, extraocular muscle movement and intraocular pressure were also evaluated. At the end of the 12 weeks, the mean CAS was not significantly decreased in the lanreotide group compared to the placebo group. The overall mean difference of proptosis between these two groups also did not reach significance at 12 weeks. Only diplopia at downward gaze had significant improvement for the lanreotide-treated group vs placebo group (p=0.03). No differences were observed between the two groups compared to other outcome measures. During the 24-month follow-up after the clinical trial, 14 patients received eye surgery in the placebo group compared with 10 patients in the lanreotide group (p=0.29). Six patients received methylprednisolone pulse therapy in the placebo group and two patients in the lanreotide group (p=0.25). In conclusion, lanreotide treatment had no significant effects on GO compared with placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 1989, 120: 473–8.

    CAS  Google Scholar 

  2. Bahn RS. Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003, 88: 1939–46.

    Article  CAS  PubMed  Google Scholar 

  3. Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med 1993, 329: 1468–75.

    Article  CAS  PubMed  Google Scholar 

  4. Diez JJ. Therapy of Graves’ ophthalmopathy: a novel application of somatostatin analogues. Expert Opin Pharmacother 2001, 2: 1361–5.

    Article  CAS  PubMed  Google Scholar 

  5. Heufelder AE, Spitzweg C. Immunology of Graves’ ophthalmopathy. Dev Ophthalmol 1999, 30: 24–38.

    Article  CAS  PubMed  Google Scholar 

  6. Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998, 8: 429–32.

    Article  CAS  PubMed  Google Scholar 

  7. Krassas GE. Somatostatin analogues in the treatment of thyroid eye disease. Thyroid 1998, 8: 443–5.

    Article  CAS  PubMed  Google Scholar 

  8. Chang TC, Kao SC, Huang KM. Octreotide and Graves’ ophthalmopathy and pretibial myxoedema. BMJ 1992, 304: 158.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Ozata M, Bolu E, Sengul A, et al. Effects of octreotide treatment on Graves’ ophthalmopathy and circulating sICAM-1 levels. Thyroid 1996, 6: 283–8.

    Article  CAS  PubMed  Google Scholar 

  10. Krassas GE. Somatostatin analogs: a new tool for the management of Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 281–7.

    CAS  PubMed  Google Scholar 

  11. Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreo-scan and correlation with MR imaging in Graves’ ophthalmopathy. Thyroid 1995, 5: 107–11.

    Article  CAS  PubMed  Google Scholar 

  12. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995, 42: 571–5.

    Article  CAS  Google Scholar 

  13. Postema PT, Krenning EP, Wijngaarde R, et al. (111In-DTPA-D-Phe1)octreotide scintigraphy in thyroidal and orbital Graves’ disease: a parameter for disease activity? J Clin Endocrinol Metab 1994, 79: 1845–51.

    Article  CAS  PubMed  Google Scholar 

  14. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab 2002, 87: 5125–9.

    Article  CAS  PubMed  Google Scholar 

  15. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol 2000, 25: 63–71.

    Article  CAS  PubMed  Google Scholar 

  16. International ad hoc committee. Classification of eye changes of Graves’ disease. Thyroid 1992, 2: 235–6.

    Article  Google Scholar 

  17. Werner SC. Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 1977, 44: 203–4.

    Article  CAS  PubMed  Google Scholar 

  18. Hettmansperger TP, McKean J. Robust nonparametric statistical methods. London: Arnold. 1998.

    Google Scholar 

  19. Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997, 136: 416–22.

    Article  CAS  PubMed  Google Scholar 

  20. Krassas GE, Doumas A, Kaltsas T, Halkias A, Pontikides N. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 1999, 9: 47–52.

    Article  CAS  PubMed  Google Scholar 

  21. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium-111-pentreotide scintigraphy in Graves’ ophthalmopathy. J Nucl Med 1995, 36: 550–4.

    CAS  PubMed  Google Scholar 

  22. Colao A, Pivonello R, Lastoria S, et al. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves’ disease. Eur J Endocrinol 2000, 143: S35–42.

    Article  CAS  PubMed  Google Scholar 

  23. Gerding MN, van der Zant FM, van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1999, 50: 373–9.

    Article  CAS  Google Scholar 

  24. Uysal AR, Corapcioglu D, Tonyukuk VC, et al. Effect of octreotide treatment on Graves’ ophthalmopathy. Endocr J 1999, 46: 573–7.

    Article  CAS  PubMed  Google Scholar 

  25. Kung AW, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves’ ophthalmopathy. Thyroid 1996, 6: 381–4.

    Article  CAS  PubMed  Google Scholar 

  26. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005, 90: 841–8.

    Article  CAS  PubMed  Google Scholar 

  27. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 5910–5.

    Article  CAS  PubMed  Google Scholar 

  28. Terwee CB, Prummel MF, Gerding MN, et al. Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2005, 62: 145–55.

    Article  CAS  Google Scholar 

  29. Feldon S. Classification of Graves’ ophthalmopathy. Thyroid 1993, 3: 171.

    Article  CAS  PubMed  Google Scholar 

  30. Gerding M, Prummel M, Wiersinga W. Assessment of disease activity in Graves’ ophthalmopathy by orbital ultra-sonography and clinical parameters. Clin Endocrinol (Oxf) 2000, 52: 641–6.

    Article  CAS  Google Scholar 

  31. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989, 73: 639–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1997, 47: 9–14.

    Article  CAS  Google Scholar 

  33. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001, 55: 283–303.

    Article  CAS  Google Scholar 

  34. Chang TC, Huang KM, Hsiao YL, et al. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves’ ophthalmopathy. Acta Ophthalmol Scand 1997, 75: 301–4.

    Article  CAS  PubMed  Google Scholar 

  35. Balazs C, Bokk A, Farid NR. Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves’ disease. Thyroid 1994, 4: 27–30.

    Article  CAS  PubMed  Google Scholar 

  36. Prummel MF, Gerding MN, Zonneveld FW, Wiersinga WM. The usefulness of quantitative orbital magnetic resonance imaging in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2001, 54: 205–9.

    Article  CAS  Google Scholar 

  37. Prummel MF, Suttorp-Schulten MS, Wiersinga WM, et al. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves’ ophthalmopathy. Ophthalmology 1993, 100: 556–61.

    Article  CAS  PubMed  Google Scholar 

  38. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 2001, 108: 1523–34.

    Article  CAS  PubMed  Google Scholar 

  39. Frueh BR. Why the NOSPECS classification of Graves’ eye disease should be abandoned, with suggestions for the characterization of the disease. Thyroid 1992, 2: 85–8.

    Article  CAS  PubMed  Google Scholar 

  40. Chen YL, Chang TC, Huang KM, et al. Relationship of eye movement to computed tomographic findings in patients with Graves’ ophthalmopathy. Acta Ophthalmol (Copenh) 1994, 72: 472–7.

    Article  CAS  Google Scholar 

  41. Hiromatsu Y, Kojima K, Ishisaka N, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992, 2: 299–305.

    Article  CAS  PubMed  Google Scholar 

  42. Durak I, Durak H, Ergin M, Yurekli Y, Kaynak S. Somatostatin receptors in the orbits. Clin Nucl Med 1995, 20: 237–42.

    Article  CAS  PubMed  Google Scholar 

  43. Doumas AS, Krassas GE, Kaltsas T, Pontikides N. Imaging somatostatin receptor activity in patients with active thyroid eye disease using Tc-99m depreotide. Clin Nucl Med 2003, 28: 439–40.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan

    T.-C. Chang MD, PhD

  2. Department of Ophthalmology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan

    S.-L. Liao

Authors
  1. T.-C. Chang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S.-L. Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T.-C. Chang MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, TC., Liao, SL. Slow-release lanreotide in Graves’ ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 29, 413–422 (2006). https://doi.org/10.1007/BF03344124

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344124

Key-words

Search

Navigation